A pioneer of the Crispr gene-editing technology that’s taken Wall Street by storm says the field is probably five to 10 years away from having an approved therapy for patients. Biochemist Jennifer Doudna, who runs the Doudna Lab at the University of California at Berkeley, says major questions remain...